Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $2.28 Analyst target: $5.12 Upside: 124.56%
Cerus Corporation, a biomedical products company, is focused on developing and commercializing the INTERCEPT Blood System to improve blood safety. The company is headquartered in Concord, California.
See the full interactive analysis & chart →Informational only — not investment advice.